Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36329558/
Orelabrutinib selectively inhibits BTK via covalent binding and exhibits linear pharmacokinetics. BTK is the only kinase targeted by orelabrutinib, and a few off-target toxicities of orelabrutinib have been reported. The phase I/II trial demonstrated the efficacy and safety of orelabrutinib in patie ...
Expert Opinion: Orelabrutinib selectively inhibits BTK via covalent binding and exhibits linear pharmacokinetics. BTK is the only kinase targeted by orelabrutinib, and a few off-target toxicities of orelabrutinib have been reported. The phase I/II trial demonstrated the efficacy and safety of orelabrutinib in patients with R/R CLL/SLL; however, further clinical trials are needed to compare orelabrutinib with ibrutinib in patients with R/R CLL/SLL and to evaluate its efficacy and safety in patients with treatment-naive CLL/SLL.
• Source: Expert Opinion on Pharmacotherapy
• Conclusions/Relevance: “Orelabrutinib selectively inhibits BTK via covalent binding and exhibits linear pharmacokinetics. BTK is the only kinase targeted by orelabrutinib, and a few off-target toxicities of orelabrutinib have been reported.”
• A phase I/II trial demonstrated the efficacy and safety of orelabrutinib in patients with R/R CLL/SLL. However, orelabrutinib needs to be compared with ibrutinib in patients with R/R CLL/SLL, as well as to assess its efficacy and safety in patients with treatment-naive CLL/SLL.
• Orelabrutinib is a novel, highly selective covalent BTK inhibitor that has proven effective and has an acceptable safety profile. It was approved for relapsed /refractory (R/R) CLL/SLL in China, where the study was performed.